Metabolic determinants of stemness in medulloblastoma

doi:10.4252/wjsc.v14.i8.587

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3444)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

180

WORD

HTML

1686

Figures (1-2)

127

Tables (1-2)

105

Sum=2140

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

221

Download

501

Sum=722

Publishing Process of This Article

Item

Count

Browse

248

Download

334

Sum=582

Aug 26, 2022 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Stem Cells. Aug 26, 2022; 14(8): 587-598
Published online Aug 26, 2022. doi: 10.4252/wjsc.v14.i8.587

Table 2 Metabolic therapeutic targeting in medulloblastoma

MB group	MB		MB-CSCs
MB group	General drug (target)	Group specific drug (target)	General drug (target)	Group specific drug (target)
WNT[2]	C75 (FASN)[36], Oxamate (LDH)[41], DFMO (ODC)¹, Isotretinoin (RAR, RXR)¹		DCA (PDK)[54]; Curcumin (pleiotropic)[73]; IP6 (mTOR)[55]
SHH[2]		GW9662 (PPARγ)[39]
Group 3[2]		GSK2837808a, FX11 (LDHA)[43]; TAK228, Sirolimus, Temsirolimus, Everolimus (mTOR)[71]; JHU395 (Glutamine)[72]		WP1066 (STAT3) & Chloroquine (autophagy)[58]
Group 4[2]

¹Compounds tested in clinical trials. DCA: Dichloroacetic acid; DFMO: Difluoromethylornithine; FASN: Fatty acid synthase; LDH: Lactate dehydrogenase; MB: Medulloblastoma; MB-CSCs: Medulloblastoma cancer stem cells; mTOR: Mammalian target of rapamycin; ODC: Ornithine decarboxylase; PPARγ: Peroxisome proliferator-activated receptor gamma; RAR: Retinoic acid receptor; RXR: Retinoid X receptor; STAT3: Signal transducer and activator of transcription 3.

Citation: Martín-Rubio P, Espiau-Romera P, Royo-García A, Caja L, Sancho P. Metabolic determinants of stemness in medulloblastoma. World J Stem Cells 2022; 14(8): 587-598
URL: https://www.wjgnet.com/1948-0210/full/v14/i8/587.htm
DOI: https://dx.doi.org/10.4252/wjsc.v14.i8.587